-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with relapsed/recurring multiple myeloma (RRMM) have exhausted the advantages of amine in the early treatment line and are in urgent need of effective treatment.
in Queue A of the Phase 2 MM-014 trial, the researchers looked at the safety and efficacy of low-dose dexamisund on patients with RRMM and previous second-line therapy immediately after the failure of the amine treatment, the results of which were published online in Br J Haematol.
4 mg of pomadamine on the first to 21st days of the 28-day cycle.
given 40mg on the first, 8th, 15th and 22nd days of the 28-day cycle (20mg for patients older than 75).
end point is total response rate (ORR), and secondary endpoints include progress-free lifetime (PFS), total lifetime (OS), and security.
56 patients were included in the intended treatment population; all patients received nadamine (87.5 percent of the drug resistance) and 39 (69.6 percent) had received boronicazome.
ORR was 32.1% (previously 28.2% for the boron-zomia group).
PFS was 12.2 months (7.9 months for the previously accepted boron Zomia group).
OS was 41.7 months (previously accepted boratezomia group was 38.6 months).
the most common level 3/4 treatment emergencies were anemia (25.0%), pneumonia (14.3%) and fatigue (14.3%).
, these results support earlier treatments based on posamamine in patients treated with RRMM, including those who are already incurable.
。
